首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   13830篇
  免费   860篇
  国内免费   69篇
耳鼻咽喉   141篇
儿科学   359篇
妇产科学   260篇
基础医学   2000篇
口腔科学   466篇
临床医学   1192篇
内科学   3147篇
皮肤病学   527篇
神经病学   1313篇
特种医学   316篇
外科学   1168篇
综合类   72篇
现状与发展   1篇
一般理论   5篇
预防医学   1681篇
眼科学   251篇
药学   981篇
中国医学   69篇
肿瘤学   810篇
  2023年   149篇
  2022年   230篇
  2021年   599篇
  2020年   328篇
  2019年   516篇
  2018年   632篇
  2017年   376篇
  2016年   366篇
  2015年   461篇
  2014年   650篇
  2013年   789篇
  2012年   1228篇
  2011年   1209篇
  2010年   676篇
  2009年   539篇
  2008年   860篇
  2007年   876篇
  2006年   727篇
  2005年   763篇
  2004年   620篇
  2003年   564篇
  2002年   515篇
  2001年   123篇
  2000年   70篇
  1999年   116篇
  1998年   89篇
  1997年   66篇
  1996年   63篇
  1995年   55篇
  1994年   34篇
  1993年   45篇
  1992年   53篇
  1991年   43篇
  1990年   28篇
  1989年   21篇
  1988年   22篇
  1987年   14篇
  1986年   12篇
  1985年   18篇
  1984年   18篇
  1983年   18篇
  1982年   8篇
  1981年   8篇
  1979年   12篇
  1978年   14篇
  1977年   11篇
  1974年   12篇
  1973年   9篇
  1969年   11篇
  1967年   8篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
7.
In low and middle-income countries mammographic breast cancer screening is prohibitively expensive and a cheaper alternative option is to use ultrasound as the primary screening test. In 2009, China launched a breast cancer screening programme for rural women aged 35–64 years with clinical breast examination coupled with ultrasound as the primary tool. Our study aimed to analyse the cost-effectiveness of breast screening compared to no screening among Chinese rural women. We developed a Markov model to estimate the lifetime costs and effects for rural women aged 35 years from a societal perspective. Asymptomatic women in the intervention arm were screened every 3 years before age 64 years. Breast cancer in the non-screening arm can only be diagnosed on presentation of symptoms. Parameter uncertainty was explored using one-way and probabilistic sensitivity analyses. Compared to no screening, breast cancer screening cost $186.7 more and led to a loss of 0.20 quality-adjusted life years (QALYs). Breast screening was more expensive and did harm to health among rural women with an incremental cost-effectiveness ratio (ICER) of $-916/QALY. The sensitivity analysis identified utility loss from false positives as the factor that most influenced the results, but this did not affect the conclusions. In a rural setting with such low breast cancer incidence, screening for asymptomatic disease is not cost-effective with current screening tools. Priority should be given to ensure that symptomatic women have proper access to diagnosis and treatment at an early stage as this will lead to mortality reductions without the usual screening harms.  相似文献   
8.
9.
IntroductionScales for predicting venous thromboembolism (VTE) recurrence are useful for deciding the duration of the anticoagulant treatment. Although there are several scales, the most appropriate for our setting has not been identified. For this reason, we aimed to validate the DASH prediction score and the Vienna nomogram at 12 months.MethodsThis was a retrospective study of unselected consecutive VTE patients seen between 2006 and 2014. We compared the ability of the DASH score and the Vienna nomogram to predict recurrences of VTE. The validation was performed by stratifying patients as low-risk or high-risk, according to each scale (discrimination) and comparing the observed recurrence with the expected rate (calibration).ResultsOf 353 patients evaluated, 195 were analyzed, with an average age of 53.5 ± 19 years. There were 21 recurrences in 1 year (10.8%, 95% CI: 6.8%-16%). According to the DASH score, 42% were classified as low risk, and the rate of VTE recurrence in this group was 4.9% (95% CI: 1.3%-12%) vs. the high-risk group that was 15% (95% CI: 9%-23%) (p <.05). According to the Vienna nomogram, 30% were classified as low risk, and the rate of VTE recurrence in the low risk group vs. the high risk group was 4.2% (95% CI:0.5%-14%) vs. 16.2% (95% CI: 9.9%-24.4%) (p <.05).ConclusionsOur study validates the DASH score and the Vienna nomogram in our population. The DASH prediction score may be the most advisable, both because of its simplicity and its ability to identify more low-risk patients than the Vienna nomogram (42% vs. 30%).  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号